(Q36577866)

15 August 2017

1 reference

title

Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications (English)

1 reference

15 August 2017

1 reference

Guy Faulkner

1

1 reference

15 August 2017

Tony A Cohn

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

Canadian Journal of Psychiatry

15 August 2017

published in

1 reference

15 August 2017

volume

51

1 reference

15 August 2017

issue

8

1 reference

15 August 2017

page(s)

502-511

1 reference

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Metabolic monitoring for patients treated with antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Pharmacogenetics of antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

The association of weight gain and olanzapine plasma concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Atypical antipsychotics and glucose dysregulation: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Nizatidine for the treatment of patients with quetiapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Amantadine for weight gain associated with olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Metformin for weight loss in pediatric patients taking psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Approach to treatment of the patient with metabolic syndrome: lifestyle therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Long-term effectiveness of weight-loss interventions in adults with pre-diabetes: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Psychological interventions for overweight or obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Schizophrenia and weight management: a systematic review of interventions to control weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Behavioural management of antipsychotic-induced weight gain: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

The Effects of an Educational Intervention on Antipsychotic‐Induced Weight Gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Schizophrenia and increased risks of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Improving the physical health of patients with schizophrenia: therapeutic nihilism or realism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

Integrating physical activity into mental health services for persons with serious mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100805

10.1177/070674370605100805

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference